It is imperative to acknowledge that our study concentrated on comparing the therapeutic efficiency of PRT + αPD1 and XRT + αPD1 in αPD1-resistant lung tumors, as most lung cancer patients exhibit resistance to anti-PD1 therapy [90]. This evidence concerns the gene PDCD1 and lung carcinoma.